New Delhi: Russian scientists have announced the development of a cancer vaccine, claiming it is ready for clinical use after years of research and successful trials. The announcement was made by Federal Medical and Biological Agency (FMBA) head Veronika Skvortsova at the 10th Eastern Economic Forum in Vladivostok, according to Russian news agency TASS.
The vaccine, named Enteromix, is based on messenger RNA (mRNA) technology, the same platform used in some COVID-19 vaccines. Unlike conventional vaccines that rely on weakened viruses, mRNA vaccines train the body’s cells to produce proteins that trigger an immune response.
In this case, the immune system is directed to attack cancer cells.
Skvortsova said the vaccine had completed three years of preclinical trials, which confirmed both its safety and efficacy. “Repeated administration of the vaccine showed no safety concerns, while effectiveness ranged from 60% to 80%, depending on the type of cancer,” she said.
In some test subjects, tumors either shrank or showed slower growth, while overall survival rates improved.The first clinical application of Enteromix will focus on colorectal cancer, a common form of cancer affecting the large intestine.
Researchers are also working on adapting the vaccine to treat glioblastoma, an aggressive brain tumor, and melanoma, including ocular melanoma, a rare but serious cancer of the eye.The announcement marks a significant step in cancer research, though experts caution that broader clinical trials and regulatory approvals will be required before the vaccine can be widely used.
The news was revealed at the Eastern Economic Forum, which this year drew more than 8,400 participants from over 75 countries, highlighting Russia’s efforts to showcase advances in science and technology on the global stage.
